doi:10.3389/fendo.2022.841889 Kouwenberg S
However, larger and longer-term studies are still needed to comprehensively evaluate its impact on key liver issues and fully assess its safety profile
In chronic kidney disease, the pivotal FLOW trial demonstrated that semaglutide 1 mg reduced the risk of major kidney events by 24% in patients with type 2 diabetes and CKD, resulting in a dedicated indication in this population
Aging- and photoaging-dependent changes of enzymic and nonenzymic antioxidants in the epidermis and dermis of human skin in vivo
Hormone optimization and mood support For men on a testosterone protocol, D3 optimization removes one potential biological drag on T levels
Whether through social media, traditional news outlets, or word of mouth, discussions about GLP-1 therapy are everywhere